Phase III trial of docetaxel cisplatin 5‐fluorouracil induction chemotherapy for resectable oral cancer suggests favorable pathological response as a surrogate endpoint for good therapeutic outcome

Detalles Bibliográficos
Autores principales: Ju, Wu‐tong, Liu, Ying, Wang, Li‐zhen, Li, Jiang, Ren, Guo‐xing, Sun, Jian, Tu, Wen‐yong, Hu, Yong‐jie, Ji, Tong, Yang, Wen‐jun, Li, Jun, He, Yue, Wang, Yan‐an, Zhang, Chen‐ping, Zhong, Lai‐ping, Zhang, Zhi‐yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Letters to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7968883/
https://www.ncbi.nlm.nih.gov/pubmed/33471949
http://dx.doi.org/10.1002/cac2.12136

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7968883/
https://www.ncbi.nlm.nih.gov/pubmed/33471949
http://dx.doi.org/10.1002/cac2.12136

Ejemplares similares